No End In Sight For M&A As Medtechs Adapt To The “New Normal”
Executive Summary
The global medtech industry may be facing slow growth, rising regulatory demands and not exactly free-flowing venture capital investment. But EY finds reasons for optimism and sees opportunities for companies able to cope with the changes and move with alacrity.
You may also be interested in...
UK Industry Must Step Up To The Challenges Of Coronavirus 'Test And Trace' Says Minister
The UK will not control COVID-19 sustainably unless it adopts new ways of doing things, health minster Lord Bethell told health care innovators.
UK MHRA In The Spotlight As Cumberlege Review Puts Medtech Safety At The Top Of Health Agenda
The findings of the Cumberlege Review into how safety issues for three medical product groups were handled will shape debate on the UK’s new devices legislation, now going through parliament. The MHRA’s devices regulatory activity also comes in for scrutiny.
UK Medtechs Fear That Pre-COVID-19 Activity May Be Over A Year Away
Top of the agenda for the medtech industry globally is when the “new normal” will return. In the UK, the expectations are that post-COVID-19 health care activity will increase gradually, but it is possible that the National Health Service will not reach its pre-coronavirus capacities until late in 2021, “if at all.”
Need a specific report? 1000+ reports available
Buy Reports